Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano (MI), Italy.
Lofarma Spa, Milano, Italy.
J Investig Allergol Clin Immunol. 2016;26(6):362-365. doi: 10.18176/jiaci.0054.
Polcalcins are highly cross-reactive pollen panallergens. Less than 10% of allergic patients are sensitized to polcalcins. All pollen species are considered able to sensitize patients to this panallergen.
We aimed to assess the presence of polcalcins in various pollen extracts used in allergen immunotherapy.
ELISA inhibition experiments were performed with sera from patients sensitized to polcalcin and rPhl p 7 and rBet v 4. Recombinant polcalcin was used as the substrate and freshly prepared pollen extracts as inhibitors.
All pollen extracts induced significant inhibition of IgE reactivity to rBet v 4, whereas only grass pollen extract induced marked inhibition of IgE reactivity to rPhl p 7.
Grass polcalcin probably contains more epitopes than polcalcins from other pollen sources. Grass pollen could be responsible for sensitization to polcalcins, and grass pollen immunotherapy is likely to be an option for polcalcin-hypersensitive patients.
多角体蛋白是高度交叉反应的花粉泛过敏原。不到 10%的过敏患者对多角体蛋白过敏。所有花粉物种都被认为能够使患者对这种泛过敏原致敏。
我们旨在评估各种用于过敏原免疫治疗的花粉提取物中多角体蛋白的存在。
用对多角体蛋白和 rPhl p 7 以及 rBet v 4 过敏的患者的血清进行 ELISA 抑制实验。重组多角体蛋白用作底物,新鲜制备的花粉提取物用作抑制剂。
所有花粉提取物均诱导对 rBet v 4 的 IgE 反应明显抑制,而只有草花粉提取物诱导对 rPhl p 7 的 IgE 反应显著抑制。
草多角体蛋白可能比其他花粉来源的多角体蛋白含有更多的表位。草花粉可能是对多角体蛋白致敏的原因,草花粉免疫疗法可能是多角体蛋白过敏患者的一种选择。